ANI Pharmaceuticals ANIP
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of ANI Pharmaceuticals (ANIP)
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Key Insights
Critical company metrics and information
Latest Closing Price
$60.62Market Cap
$1.27 BillionPrice-Earnings Ratio
-58.29Total Outstanding Shares
20.96 Million SharesTotal Employees
642Dividend
No dividendIPO Date
September 13, 1999SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQType
Common StockHeadquarters
210 main street west, Baudette, MN, 56623Homepage
https://www.anipharmaceuticals.com
Historical Stock Splits
If you bought 6 shares of ANIP before June 4, 2012, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| June 4, 2012 | 1-for-6 (Reverse Split) |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $64.02 Million |
| Net Cash Flow From Operating Activities | $64.02 Million |
| Net Cash Flow From Financing Activities, Continuing | $264.94 Million |
| Net Cash Flow, Continuing | $-75.76 Million |
| Net Cash Flow | $-76.23 Million |
| Exchange Gains/Losses | $-470,000 |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Income Tax Expense/Benefit, Current | $17.82 Million |
| Diluted Average Shares | $19.32 Million |
| Income/Loss From Continuing Operations Before Tax | $-22.21 Million |
| Net Income/Loss | $-18.52 Million |
| Income Tax Expense/Benefit, Deferred | $-23.00 Million |
| Costs And Expenses | $613.79 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-22.04 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-22.04 Million |
| Other Comprehensive Income/Loss | $-3.51 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Current Assets | $372.93 Million |
| Current Assets | $527.68 Million |
| Liabilities And Equity | $1.28 Billion |
| Noncurrent Assets | $756.01 Million |
| Equity | $403.68 Million |
| Assets | $1.28 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about ANIP from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.